Rubitecan: Difference between revisions
Citation bot (talk | contribs) Alter: title, template type. Add: pages, issue, volume, doi, year, journal, author pars. 1-2. Removed URL that duplicated unique identifier. Removed accessdate with no specified URL. Removed parameters. Formatted dashes. Some additions/deletions were actually parameter name changes. | You can use this bot yourself. Report bugs here. | Suggested by Abductive | Category:Abandoned drugs | via #UCB_Category |
tweak cites |
||
Line 18: | Line 18: | ||
| metabolites = 9-Aminocamptothecin (9-AC) |
| metabolites = 9-Aminocamptothecin (9-AC) |
||
| elimination_half-life = 15–18 hours (rubitecan), 18–22 hours (9-AC) |
| elimination_half-life = 15–18 hours (rubitecan), 18–22 hours (9-AC) |
||
| excretion = [[Bile]] and [[feces]] (major proportion), [[urine]] (the minor one)<ref>{{cite web|title=Withdrawal Assessment Report for Orathecin (rubitecan). Applicant: EuroGen Pharmaceuticals, Ltd.|url=http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500069806.pdf|publisher=European Medicines Agency| |
| excretion = [[Bile]] and [[feces]] (major proportion), [[urine]] (the minor one)<ref>{{cite web|title=Withdrawal Assessment Report for Orathecin (rubitecan). Applicant: EuroGen Pharmaceuticals, Ltd.|url=http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500069806.pdf|publisher=European Medicines Agency|access-date=15 July 2016|pages=4–8|date=30 November 2007}}</ref> |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
Line 51: | Line 51: | ||
==History== |
==History== |
||
On January 27, 2004, SuperGen announced that it has completed the submission of an NDA for rubitecan to the US FDA,<ref>{{cite web |url=https://www.drugs.com/nda/orathecin_040128.html | |
On January 27, 2004, SuperGen announced that it has completed the submission of an NDA for rubitecan to the US FDA,<ref>{{cite web |url=https://www.drugs.com/nda/orathecin_040128.html | work = Drugs.com | title = SuperGen completes submission of New Drug Application (NDA) for Orathecin as an oral treatment for pancreatic cancer |access-date=2008-03-25 |format= }}</ref> and was accepted for filing on March 2004.<ref>{{cite web |url=https://www.drugs.com/nda/orathecin_040326.html |work = Drugs.com | title = SuperGen's New Drug Application for Orathecin (rubitecan) capsules accepted by FDA for filing |access-date=2008-03-25 |format= }}</ref> |
||
In January 2005, and under the direction of then-CEO James Manuso, SuperGen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval,<ref>{{cite web |url=https://www.drugs.com/nda/orathecin_050103.html | |
In January 2005, and under the direction of then-CEO James Manuso, SuperGen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval,<ref>{{cite web |url=https://www.drugs.com/nda/orathecin_050103.html |work = Drugs.com | title = SuperGen Announces Withdrawal of Orathecin NDA |access-date=2008-03-25 |format= }}</ref> and on January 2006, the Marketing Authorization Application (MAA) filed with the [[European Medicines Agency]] (EMA) was also withdrawn.<ref>{{cite web |url=http://www.emea.europa.eu/humandocs/PDFs/EPAR/orathecin/2621906en.pdf |title=Press release from the EMEA website regarding withdrawal of Orathecin MAA |access-date=2008-03-25 |url-status=dead |archive-url=https://web.archive.org/web/20070611123027/http://www.emea.europa.eu/humandocs/PDFs/EPAR/orathecin/2621906en.pdf |archive-date=2007-06-11 }}</ref> |
||
The name Rubitecan is a portmanteau of SuperGen's founder, [[Dr. Joseph Rubinfeld]], and the chemical name 9-Nitrocamptothecin. |
The name Rubitecan is a portmanteau of SuperGen's founder, [[Dr. Joseph Rubinfeld]], and the chemical name 9-Nitrocamptothecin. |
||
==Synthesis== |
==Synthesis== |
||
Large scale production of Rubitecan has encountered problems. The direct nitration of camptothecin results in regioselectivity problems. One way that has been used to synthesize Rubitecan is to nitrate 10-hydroxycamptothecin than remove the hydroxyl functional group.<ref>{{cite journal |title=A Practical Regiospecific Synthesis of 9-Nitrocamptothecin |journal= Synthesis|year=2006 |doi=10.1055/s-2006-942359 | |
Large scale production of Rubitecan has encountered problems. The direct nitration of camptothecin results in regioselectivity problems. One way that has been used to synthesize Rubitecan is to nitrate 10-hydroxycamptothecin than remove the hydroxyl functional group.<ref>{{cite journal |title=A Practical Regiospecific Synthesis of 9-Nitrocamptothecin |journal= Synthesis|year=2006 |doi=10.1055/s-2006-942359 | vauthors = Chen Z, Fu Q |volume=2006 |issue=12 |pages=1940–1942 }} </ref> |
||
==Use as Anti-Cancer Drug== |
==Use as Anti-Cancer Drug== |
||
Rubitecan is a compound used extensively in cancer research. Rubitecan is an effective drug against pancreatic cancer and other solid tumors. One major problem is the lack of oral bioavailability due to low permeability and poor water solubility. One study shows 9-NC-SD through Soluplus1-based solid dispersion system is a much more effective delivery method than free 9-NC.<ref>{{cite |
Rubitecan is a compound used extensively in cancer research. Rubitecan is an effective drug against pancreatic cancer and other solid tumors. One major problem is the lack of oral bioavailability due to low permeability and poor water solubility. One study shows 9-NC-SD through Soluplus1-based solid dispersion system is a much more effective delivery method than free 9-NC.<ref name="pmid25445521">{{cite journal | vauthors = Lian X, Dong J, Zhang J, Teng Y, Lin Q, Fu Y, Gong T | title = Soluplus(®) based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation | journal = International Journal of Pharmaceutics | volume = 477 | issue = 1-2 | pages = 399–407 | date = December 2014 | pmid = 25445521 | doi = 10.1016/j.ijpharm.2014.10.055 }}</ref> |
||
==References== |
== References == |
||
{{Reflist}} |
{{Reflist}} |
||
Revision as of 07:27, 20 September 2020
![]() | |
Clinical data | |
---|---|
Trade names | Orathecin |
Other names | 9-Nitrocamptothecin 9-NC 9-nitro-20(S)-camptothecin Camptogen (19S)-19-Ethyl-19-hydroxy-10-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione |
Routes of administration | Oral (capsules) |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 25–30% (rubitecan and 9-AC; in dogs) |
Protein binding | 97% (rubitecan), 65% (9-AC) |
Metabolism | Probably CYP-dependent |
Metabolites | 9-Aminocamptothecin (9-AC) |
Elimination half-life | 15–18 hours (rubitecan), 18–22 hours (9-AC) |
Excretion | Bile and feces (major proportion), urine (the minor one)[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H15N3O6 |
Molar mass | 393.355 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by SuperGen (now Astex Pharmaceuticals, Inc.; a member of the Otsuka Group).
History
On January 27, 2004, SuperGen announced that it has completed the submission of an NDA for rubitecan to the US FDA,[2] and was accepted for filing on March 2004.[3]
In January 2005, and under the direction of then-CEO James Manuso, SuperGen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval,[4] and on January 2006, the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) was also withdrawn.[5]
The name Rubitecan is a portmanteau of SuperGen's founder, Dr. Joseph Rubinfeld, and the chemical name 9-Nitrocamptothecin.
Synthesis
Large scale production of Rubitecan has encountered problems. The direct nitration of camptothecin results in regioselectivity problems. One way that has been used to synthesize Rubitecan is to nitrate 10-hydroxycamptothecin than remove the hydroxyl functional group.[6]
Use as Anti-Cancer Drug
Rubitecan is a compound used extensively in cancer research. Rubitecan is an effective drug against pancreatic cancer and other solid tumors. One major problem is the lack of oral bioavailability due to low permeability and poor water solubility. One study shows 9-NC-SD through Soluplus1-based solid dispersion system is a much more effective delivery method than free 9-NC.[7]
References
- ^ "Withdrawal Assessment Report for Orathecin (rubitecan). Applicant: EuroGen Pharmaceuticals, Ltd" (PDF). European Medicines Agency. 30 November 2007. pp. 4–8. Retrieved 15 July 2016.
- ^ "SuperGen completes submission of New Drug Application (NDA) for Orathecin as an oral treatment for pancreatic cancer". Drugs.com. Retrieved 2008-03-25.
- ^ "SuperGen's New Drug Application for Orathecin (rubitecan) capsules accepted by FDA for filing". Drugs.com. Retrieved 2008-03-25.
- ^ "SuperGen Announces Withdrawal of Orathecin NDA". Drugs.com. Retrieved 2008-03-25.
- ^ "Press release from the EMEA website regarding withdrawal of Orathecin MAA" (PDF). Archived from the original (PDF) on 2007-06-11. Retrieved 2008-03-25.
- ^ Chen Z, Fu Q (2006). "A Practical Regiospecific Synthesis of 9-Nitrocamptothecin". Synthesis. 2006 (12): 1940–1942. doi:10.1055/s-2006-942359.
- ^ Lian X, Dong J, Zhang J, Teng Y, Lin Q, Fu Y, Gong T (December 2014). "Soluplus(®) based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation". International Journal of Pharmaceutics. 477 (1–2): 399–407. doi:10.1016/j.ijpharm.2014.10.055. PMID 25445521.